Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003850 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00003850: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00003850 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003850, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer by stopping blood flow to the tumor.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 1999-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003850
The ClinicalTrials.gov registry entry for NCT00003850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00003850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003850 about?
NCT00003850 is a clinical study titled "Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer by stopping blood flow to the tumor.
What is the current status of trial NCT00003850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 1999-04.
What interventions are being tested in trial NCT00003850?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00003850?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.